Motley Fool
0
All posts from Motley Fool
Motley Fool in Motley Fool,

Is This Why Glaukos Corp. Is Tumbling Today?

What happened

Shares of Glaukos (NYSE: GKOS), a medical-device company focused on glaucoma, fell 12% as of 3:25 p.m. EST on Tuesday on heavy volume. However, there wasn't any news that can help to explain the move. 

So what

Glaukos shares have been under pressure ever since management knocked down the company's growth projections in September.

Once upon a time, management was projecting that full-year sales would land between $162 million to $167 million. That range implied growth of 44% at the midpoint. However, the company later stated that changes in the reimbursement environment, hurricanes, and competitive pressure were going to make it hard for the company to hit that number. As a result, they dialed back their revenue guidance range to $155 million to $160 million. While that still represents strong year-over-year growth, Wall Street didn't take the update well.

With Glaukos expected to report third-quarter earnings results later today, it's possible that some traders believe that another downward revision to guidance could be on the way. That worry could be the source of today's carnage.

Image source: Getty Images.

Now what

Glaukos' iStent put up impressive growth numbers since its launch a few years ago. However, that growth mostly came in the absence of competition. Now that Novartis' CyPass Micro-Stent is on the market, Glaukos is squaring off against a well-financed competitor.

Can the company keep its high growth rate going, or will investors be in for another round of disappointing news? We'll know more after the company reports its third-quarter earnings later today.

10 stocks we like better than Glaukos
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Glaukos wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of November 6, 2017

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.